RxDoctor Payments Data

Brett Smith, MD

Ophthalmology · Concord, NHNPI 1689939795

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $200 of the $237 with a category attached, or 84.5%. 7 manufacturers reported payments, led by RMR Ortho Inc at 40.5% of the total. 2025 is the largest year on record at $96, 2.6 times the $37 reported in 2020. That places this record below the midpoint for ophthalmology clinicians in NH, where the typical reported total is $750.

$237in general payments, 2019–2025

Across 8 payments — averaging $29.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • RMR Ortho Inc$96
  • Alcon$40
  • Bausch & Lomb Americas Inc.$25
  • Rayner Intraocular Lenses Limited$21
  • Carl Zeiss Meditec AG$19
  • AbbVie$19
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$20085%
  • Gifts$3715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$237 in reported general payments places this provider in the 30th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$309,472
Medicare patients
1,088
Services billed
2,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$37,457
Bromfenac Sodium203$22,223
Prednisolone Acetate356$14,361
Cyclosporine39$13,018
Ofloxacin409$3,601
Latanoprost188$1,522
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat52$1,053
Timolol Maleate66$868
Travoprost11$563
Doxycycline Hyclate14$497
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$193
ErythromycinErythromycin Base24$189
Brimonidine Tartrate21$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$19$37,45744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →